Biopharma AI
By
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack Drug Discovery?
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using AI to Unlock Sex-Specific Drug Combos for Aortic Valve Disease?
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the Map of Chiral Drug Discovery?
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next Breakthrough in Atopic Dermatitis Treatment?
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
Can Syntis Bio’s $38M Series A Transform Oral Biologics for Obesity and Rare Diseases?
Key Highlights Funding to Advance Novel Oral TherapiesBoston-based Syntis Bio announced the close of its $38 million financing…
Can Argon AI’s $5.5M Funding Transform Biopharma with an AI-Native Workspace to End Data Drudgery?
Key Takeaways Argon AI Secures Strategic Backing for AI-Native Biopharma WorkspaceArgon AI has raised $5.5 million in a…
